HDAC inhibitors comprising of hydroxamic moiety have been validated to be a promising novel targets for the treatment of solid tumors and hematological cancers but off-late their role has also been established toward polyglutamine disorders such as Huntington's. Here, HDAC9 is linked to hematopoietic and lymphoid cell neoplasm.